Select language

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

Milano , 12/14/2021

Companies will collaborate on manufacturing and research and development for future indications, and will commercialize Gadopiclenol independently under separate brands
Gadopiclenol is a next-generation, macrocyclic contrast agent with high-relaxivity, intended to improve lesion detection and visualization in MRI, with lower doses of gadolinium compared to other agents on the market
Guerbet and Bracco Imaging will seek regulatory approval to market Gadopiclenol in the United States and the European Union in 2023, with other geographies to follow